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ABSTRACT
Objective: This study aims to formulate a cost model from a
provider perspective regarding the direct medical costs for
diabetic patients who received care in a 30-bed public hos-
pital in Thailand during the ﬁscal year of 2001.
Methods: This study is a retrospective prevalence-based cost
of illness study. Data were collected by reviewing the medical
record of each patient for the whole year. The statistical
analysis employed was the stepwise multiple regression
method.
Results: The study covered 186 diabetic patients. It was
found that the average cost of caring for a diabetic patient per
year was 6331 Thai baht (THB) at 2001 prices (approxi-
mately 40 THB = US $1). A major portion of this cost was
spent for pharmacy services, which accounted for 45% of the
whole cost, followed by outpatient services (24%), inpatient
services (16%), and laboratory investigation (11%). Regard-
ing the model for forecasting the cost, the type of diabetes
and its accompanying complications, i.e., hyperlipidemia,
cardiovascular accident, hypertension, hyperglycemia, hypo-
glycemia, gangrene, and diabetic foot, were considered as
signiﬁcant predictor variables (adjusted R2 = 0.48). The
quantitative effects in monetary term of these signiﬁcant pre-
dictors were also demonstrated.
Conclusions: The results could be beneﬁcial in forecasting
the economic burden of diabetes mellitus in Thailand. Fur-
thermore, the results could be used as a ﬁnancial tool for cost
control and disease management at the community hospital
level.
Keywords: cost model, diabetes mellitus, direct medical cost,
hospital, Thailand.
Introduction
Diabetes mellitus is a chronic disease that occurs in
people around the world, and the trend of the inci-
dence rate has increased over time [1,2]. In relation to
this, one study attempted to estimate the global preva-
lence of diabetes by using the data available from
published prevalence studies and information on the
demographic characteristics of each country around
the world. The study forecasted that there would be
about 220 million people, which is 3.2% of the world
population, suffering from diabetes by the year 2010
[3]. Aside from health problems, diabetes also imposes
a heavy economic burden because it affects not only
individuals and their families, but also the entire
society. Because of these consequences, studies on the
economics of diabetes have been continuously done in
different countries around the world [4–11].
In Thailand, diabetes was ranked ﬁfth and third of
the top 10 diseases among males and females, respec-
tively, based on disability-adjusted life-years in 1999
[12]. In terms of prevalence, a national health exami-
nation survey done in 2004 revealed that the diabetes
prevalence was 6.4% among males and 7.3% among
females aged 15 years and above. People were charac-
terized as having the illness if they had an increased
blood sugar of greater than 126 mg/dL, or if they were
currently taking oral antiglycemics or insulin [13].
Nevertheless, study about cost of illness is rarely
conducted in Thailand. The researcher was aware of
only one study conducted in seven government hospi-
tals located in four regions of the country and in
Bangkok [14]. Another study focused on patients’
expenses as they used complementary and alternative
medicine [15]. Nevertheless, these studies were focused
on the patients’ perspective and not on that of the
providers. Hospitals in Thailand directly receive pro-
vider payments from the Social Security Ofﬁce, the
Comptroller General’s Department and the National
Health Security Ofﬁce for private employees under
the Social Security Scheme, civil servants under the
Medical Beneﬁt Scheme, and the rest of the population
under the Universal Coverage of Health Care Scheme,
respectively. Nevertheless, in the study year (2001),
there was no Universal Coverage of Health Care
Scheme. There were only health welfare schemes for
the poor and the elderly. In addition, there were those
who voluntarily procured health insurance for them-
selves, and those who had no insurance and welfare
(out-of-pocket). With these in mind, the present study
aimed to formulate a cost model of the direct medical
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costs [16] incurred by diabetic patients who received
care at Ampawa Hospital, a 30-bed public hospital in
Samutsongkram, a central province of Thailand.
Methods
Population
The target population consisted of patients with dia-
betes, deﬁned as one who has plasma glucose at a level
of at least 126 mg/dL by the fasting plasma glucose test
[17]. A 30-bed public hospital in central Thailand was
purposively selected based on convenience and accep-
tance of the hospital director. Diabetic patients belong
to all age groups in both sexes and with either type 1
and type 2 diabetes, who received treatment during
the ﬁscal year 2001 (October 1, 2000–September 30,
2001), were included in the study. Patients who had
incomplete medical records or discontinuous treat-
ment were excluded.
Research Hypothesis
Direct medical costs were associated with several inde-
pendent variables. These included age, sex, payment
scheme, type of diabetes, and type of complications.
Therefore,
DMC f age, sex, payment scheme, type of
diabetes, type of complica
= (
tions)
where
DMC direct medical cost=
Study Design
Since there was no standard unit cost of medical ser-
vices, this study thus started with a calculation of the
unit cost of the medical services given by the hospital.
Afterward, the service utilization of each individual
patient was collected to help calculate the direct
medical costs. Finally, the cost model was formulated.
Our calculation of the unit cost of medical service
employed the standard costing approach [18,19]. The
calculation was composed of ﬁve steps, i.e., organiza-
tion analysis and cost center classiﬁcation, direct cost
determination, indirect cost determination, full cost
determination, and calculation of the unit cost of
medical services [20,21].
The hospital’s departments were categorized into 13
patient-service or production cost centers, and 14
nonpatient-service or supporting cost centers. For the
direct cost determination of each cost center, the capital
cost was computed as the equivalent annual economic
cost [18,22] with a 3% discount rate as recommended
by the World Health Organization guidelines [23].
Useful lives were 5 years and 20 years for capital items
and buildings, respectively [24,25]. The indirect cost,
which is the same as the cost of supporting cost centers,
was distributed to the production cost centers through
the simultaneous allocation method [18]. The services
or outputs of the supporting cost centers were selected
as allocation criteria for the appropriation, e.g., the
number of staff for each administration department.
The average method and microcosting of departmental
allocation were employed for departments producing
homogeneous and heterogeneous products, respec-
tively [26,27]. Microcosting is a method to allocate the
cost of production of the cost center to each unit of
service. The ﬁrst step was to value the resources directly
consumed by each unit of service. Then the shared cost
of the cost center was allocated to the services in
proportion to the direct cost of the services.
For cost of illness, the study was based on the
providers’ perspective [28] employing the bottom-up,
prevalence-based approach [16]. The research covered
provider costs or direct medical costs including com-
plications but not comorbidities [16].
Sample Size
The sample size for cost function analysis was calcu-
lated based on the following equation [29]:
n at least IV( ) = ×5
where n = sample size, IV = number of independent
variable.
From the hypothesis, there were 22 independent
variables, so the minimum sample size was 110 cases.
The study included 186 people with diabetes.
Variables
The variables included in this study were demographic
characteristics, clinical status, types and quantities of
medical services, drugs and medical supplies received
(detailed in Table 1). The demographic characteristics
included sex, age, and insurance scheme. Clinical
status included the type of diabetes (type 1 or type 2)
and the type of complications because these factors
affect medical service utilization [17]. The types of
medical services consisted of services from outpatient
visits, inpatient stay, home health-care visits, pharmacy
services, laboratory investigation, emergency services,
and surgical services. The overall cost of drugs and
medical supplies is composed of the acquisition cost
and the dispensing cost. The total direct medical costs
were calculated through a summation of medical
service costs, and drugs and medical supplies costs.
The medical service cost is the result of multiplying the
number of services (e.g., outpatient visit, hospitaliza-
tion service, drug dispensing, surgery and laboratory
investigations) by their unit costs from the part of
medical service cost calculation. The cost of drugs and
medical supplies was calculated through the summa-
tion of the quotients produced by multiplying the
quantities of each drug and medical supply by its
acquisition unit cost.
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where TCn is the total direct medical costs for patient
n, QSnj is the number of medical service j used by
patient n, USj is the unit cost of medical service j, QDnk
is the number of drug k used by patient n, UDk is the
acquisition unit cost of drug k, QMnl is the number of
medical supply l used by patient n, UMl is the acqui-
sition unit cost of medical supply l.
Data Collecting Method
The resources consumed as well as the outputs pro-
duced by all of the hospital’s departments during the
ﬁscal year 2001 (October 1, 2000–September 30,
2001) were collected to calculate the unit cost of
medical services. The medical history consisting of
both outpatient and inpatient medical records was
reviewed for the whole study year to record the
patients’ demographic characteristics, clinical status,
types and quantities of medical services received, and
the types and quantities of drugs and medical supplies
used. As for records pertaining to the acquisition cost
of drugs and medical supplies, they were collected
from the pharmacy department and medical material
department, respectively.
Analysis
Descriptive statistics was used to summarize data on
demographic characteristics, clinical status, and costs.
The stepwise multiple regression analysis [30] method
was also employed to analyze the relationship between
the direct medical cost (dependent variable) and
several potential explanatory variables (independent
variables). These variables were selected based on
expert opinion. A model was then formulated to esti-
mate the direct medical cost of each patient. In the
modeling, independent variables with a probability
value of F statistics less than 0.05 on the analysis were
entered. The statistic’s assumptions and model check-
ing were examined, i.e., normal distribution, multicol-
linearity, inﬂuential observations, and outliers [30].
Sensitivity Analysis
To analyze the uncertainty of the results due to the
sample data, the one-way simple sensitivity analysis
was used [31–33]. Drug prices in Thailand were highly
varied among brand-name drugs and local-made
generic drugs. So the maximum and minimum drug
prices from the referent drug list in the ﬁscal year 2001
of the Ministry of Public Health were used for the
sensitivity analysis.
Results
Unit Costs of Medical Services
In 2001, the total cost for the hospital was 28.4 million
Thai baht (THB) at 2001 prices (approximately
40 THB = US $1). The cost can be broken down as
11% capital cost, 60% labor cost, and 29% material
cost. The unit costs of an outpatient service (per
visit) and hospitalization (per patient-day) were
125.00 THB and 993.94 THB, respectively. For a
home health-care visit, the unit cost was approxi-
mately half of that of hospitalization day. The cost was
relatively high because the number of service was rela-
tively low. It spent approximately 1 day for one visit.
As for the unit cost of pharmacy service, it was sepa-
rated into two further divisions: the cost of dispensing
and actual cost of the drugs. The details of the unit cost
per medical service received by diabetic patients are
demonstrated in Table 2.
Patient Characteristics and Service Utilization
There were totally 298 patients in the study year. One
hundred twelve patients did not receive continuous
Table 1 Description of variables (N = 186)
Variable and sample characteristics
Natural logarithmic of the cost:Thai baht (THB)
Sex: female = 62%
Age: mean = 62 years
Insurance schemes were recoded as dummy variables
(reference = welfare scheme for poor, elderly, priest, 45.7%).
Civil servant medical beneﬁt scheme: 28.5%
Social security scheme for private employees: 1.6%
Voluntary health insurance: 19.9%
Self-payment (out-of-pocket): 4.3%
Type of diabetes mellitus: type 2 = 95.7%
Types of complications
Hypertension: 41.1%
Neuropathy: 35.5%
Hyperlipidemia: 16.1%
Diabetic foot: 13.4%
Nephropathy: 7.0%
Ishemic heart disease: 4.3%
Cerebrovascular accident: 3.8%
Hyperglycemia: 2.7%
Hypoglycemia: 1.1%
Gangrene: 0.5%
Retinopathy: 0.5%
Table 2 Unit cost of medical services and drugs commonly
used by diabetic patients
Medical services
Unit cost:THB
(plausible range)
Routine service in outpatient clinics (visit) 125.00
Hospitalization, hotel cost with routine
nursing care (day)
993.94
Home health care (visit) 570.78
Drug dispensing, not including drugs
(prescription)
74.72
Fasting blood sugar (test) 50.54
Insulin NHH 10 cc 310.3 (150.70–310.30)
Insulin RI 10 cc 310.3 (274.31–310.30)
Glibenclamide 5 mg tablet 0.41 (0.10–1.61)
Metformin 500 mg tablet 0.54 (0.19–0.93)
Vitamin B1-6-12 tablet 0.38 (0.18–2.65)
Vitamin Bcomplex tablet 0.12 (0.11–0.20)
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treatment from the study hospital nor had incomplete
medical record. One hundred eighty-six patients were
included in the study. The patients were mostly females
(61.8%) (Table 1). The mean age of those reviewed
was 61.99 years. Ninety-six percent had type 2 diabe-
tes, and about three-fourths of these patients had com-
plication(s). Most of these complications included
hypertension (41.4%), followed by neuropathy
(35.5%). Additionally, the average hospitalization was
1.03 days and the average number of outpatient
department visit was 12.23 (the visits covered diabetic
wound dressing and some insulin injections). In
Table 3, it is shown that the direct medical cost con-
sisted of the cost of outpatient services, inpatient
services, pharmacy, laboratory, emergency, surgery ser-
vices, and home health care. The major cost was in
pharmacy, because it included drugs and pharmaceu-
tical services (an average of 2804 THB per person per
year), followed by outpatient services (an average of
1528 THB per person per year). The total direct
medical cost was 6331 THB per person per year. For
home health care, the average cost per patient per year
was less than its unit cost. This is because the average
service utilization per patient per year was less than
one.
Regarding sensitivity analysis, drug prices were
considered. The prices of all drugs in the treatment of
diabetes and its complication were recalculated. The
maximum and minimum prices of drugs (Table 2) pur-
chased were used in recalculating the total drug costs
and average direct medical cost. The results indicated
changes in drug costs and average direct medical cost.
When the minimum and maximum prices of drugs
were used in the recalculation, the total drug costs
yielded between 172,053.98 THB (48.67% decrease)
and 719,335.62 THB (114.59% increase), respec-
tively. This affected average direct medical costs with a
14.91% decrease and a 23.30% increase.
The cost models were formulated as a forecasting
model, and the total direct medical cost as a dependent
variable was not normally distributed. Therefore, a
natural logarithmic transformation was undertaken.
The potential predictor variables were reviewed in
Table 1. The ﬁtted model is shown in Table 4 with an
adjusted R2 = 0.480 (R2 = 0.50), and the probability of
F-test = 0.000. The signiﬁcant predicting variables
were the type of diabetes and its complications. For
assumption tests and model diagnosis, a scatter plot
of residuals against predicted values and all indepen-
dent variables showed no funnel shape indicating
homoscesdasticity [30]. Regarding the test of indepen-
dence of the residual, the Durbin-Watson value was
1.938. This indicated that the model met the assump-
tion of independence of the residual (the criteria was
1.5–2.5) [34]. The condition index was 12.499. This
met the criteria of less than 30 which indicates no
multicollinearity [30]. Cook’s Distance had a range of
0.000–0.190. This met the criteria of less than 1 which
indicates no inﬂuential observation [30].
The estimation of the expected response on the
untransformed scale after ﬁtting a linear regression
model of the transformed scale needs to be adjusted
(multiplication) by means of a smearing factor [35].
The smearing factor is the mean of anti log (exponen-
Table 3 Composition of direct medical cost (N = 186)
Medical services Mean (THB) 95% CI; lower 95% CI; upper Median
Pharmacy services 2803.99/45% 2440.91 3167.07 1927.78
Outpatient services 1528.21/24% 1471.30 1585.12 1499.98
Inpatient services 1020.65/16% 243.36 1797.95 0.00
Laboratory 712.95/11% 657.07 768.83 604.83
Emergency and surgical services 197.32/3% 78.25 316.40 0.00
Home health care 67.51/1% 20.73 114.30 0.00
Total 6330.64/100% 5300.70 7360.57 4257.45
Table 4 Fitted explanatory direct medical cost model (N = 186)
Unstandardized
coefﬁcients
t Sig.
95% CI for B
B SE Lower bound Upper bound
Constant 9.099 0.170 53.440 0.000 8.763 9.435
Type of diabetes mellitus (type 2 = 1) -0.913 0.169 -5.417 0.000 -1.245 -0.580
Hyperlipidemia 0.358 0.093 3.836 0.000 0.174 0.542
Cerebrovascular accident 0.948 0.177 5.357 0.000 0.599 1.297
Hypertension 0.149 0.069 2.174 0.031 0.014 0.285
Hyperglycemia 0.729 0.215 3.391 0.001 0.305 1.154
Gangrene 1.201 0.453 2.653 0.009 0.308 2.095
Diabetic foot 0.633 0.101 6.282 0.000 0.434 0.832
Hypoglycemia 0.893 0.344 2.597 0.010 0.215 1.572
Adjusted R2 = 0.480, probability of F-test = 0.000. SE, standard error.
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tial) form of the unstandardized residuals [36]. The
smearing factor of the ﬁtted model was 1.1244. In
forecasting for a simulated patient with type 2 dia-
betes with no complications, the predicted cost was
4036.97 THB. To explore economic effect of the com-
plications, treatment costs of patients with various
complications were estimated as presented in Table 5.
The treatment cost for a patient with type 2 diabetes
without complication was approximately 4000 THB.
The patient with hypertension consumed an additional
16% of cost of the patient without complication. The
cost increased up to 232% for the case of gangrene.
Discussion
The study found that the annual average treatment
cost of diabetic patient was 6331 THB or approxi-
mately US $158 at 2001 prices (40 THB = US $1). The
highest proportion of the treatment cost was related to
pharmacy services (45%), and the proportions of out-
patient services, inpatient services, and laboratory
investigation were 24%, 16%, and 11%, respectively.
The forecasting cost model demonstrated that type of
diabetes and its accompanying complications (i.e.,
hyperlipidemia, cardiovascular diseases, hypertension,
hyperglycemia, hypoglycemia, gangrene, and diabetic
foot ulcer) were signiﬁcant predictor variables
(adjusted R2 = 0.48).
Regarding the cost comparison, Ettaro et al. [5]
stated in the review article titled “Cost-of-illness
studies in diabetes mellitus” that:
Healthcare components considered in the direct
cost calculations vary between the studies. Nearly
all of the studies included costs associated with
hospital care, physician services and prescription
drugs, but there are marked discrepancies with
respect to inclusion of long-term care, emergency
department services, home healthcare and other
services.
Based on the review aforementioned, this study
covers complete components of direct medical costs of
diabetic care.
The results of the sensitivity analysis indicated con-
siderable changes in average direct medical costs. The
variation range was 38.21% (23.30 increases and
14.91 decreases). In Thailand, hospitals have their
own purchasing unit. In addition, there are many pro-
ducers for each drug, both local and original, which
create price variations. Based on the sample in Table 2,
the price differences are approximately 1 to 15 times in
the cases of insulin RI and vitamin B1-6-12, respectively.
Because price variations generally occur in other coun-
tries [37], the administrators or researchers who aim to
use the results of this study for comparison should thus
keep in mind the differences of prices of drugs between
hospitals.
The forecasting of the direct medical cost model
showed signiﬁcant predictor variables consisting of the
type of diabetes and its complications. For the type of
diabetes, the result showed that the cost of patients
with type 1 diabetes was more than the cost of those
with type 2 diabetes, when other explanatory variables
were constant. This could be explained by the fact that
patients with type 1 diabetes used insulin in exact
amounts, even if most of them were unable to inject
themselves. Thus, they had to go to the hospital for
insulin injections every day. Because of this, direct
medical costs would increase because of the high cost
of insulin injection and hospital services. There are
studies conﬁrming the higher cost of type 1 than type
2 diabetes [38,39].
Regarding complications, the actual economic
burden of diabetic care without covering the cost of
complications was underestimated [40–42]. This study
conﬁrmed such ﬁndings. Gangrene was the highest
economic burden among all of the complications
because it requires surgical treatment. Preventing the
occurrence of gangrene created savings of nearly
10,000 THB per patient-year (232% of the case
without complications; see Table 5). Studies in India
showed that the treatment expenditure of diabetic
patients with foot complications was signiﬁcantly
higher than those without the complications [43,44].
Similarly, many studies showed that diabetic patients
with diabetic foot ulcer had signiﬁcantly higher health-
Table 5 Predicted cost of various clinical statuses (N = 186)
Clinical status Cost (THB) Cost increase (THB)* Percentage increase
1. Diabetes type 2, no complication 4,036.97 —
2. Diabetes type 2 with hypertension 4,685.60 648.63 16.07
3. Diabetes type 2 with hyperlipidemia 5,774.75 1,737.78 43.05
4. Diabetes type 2 with diabetic foot 7,602.63 3,565.66 88.33
5. Diabetes type 2 with hyperglycemia 8,368.66 4,331.69 107.30
6. Diabetes type 2 with hypoglycemia 9,860.08 5,823.11 144.24
7. Diabetes type 2 with cerebrovascular accident 10,417.57 6,380.61 158.05
8. Diabetes type 2 with gangrene 13,416.62 9,379.65 232.34
9. Diabetes type 1, no complication 10,059.27 6,022.30 149.18
*Clinical status 1 is a base-case.
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care costs [40,45–49]. Costs due to the complications
attribute to the largest fraction of diabetic care [50].
Based on the economic effects of these complications,
it would be quite challenging to conduct complication-
preventing measures.
To compare the cost models with those of other
studies, one study conducted a cost model of patients
with type 2 diabetes from a large group-model health
maintenance organization during the period between
1987 and 1995 in the United States [51]. The potential
explanatory variables were age, sex, stages of renal
complication, and stages of cardiovascular complica-
tion. The result indicated that sex, all stages of renal
complication, and all stages of cardiovascular compli-
cation were in fact signiﬁcant explanatory variables.
The results of our study were consistent with such a
study indicating that costs were positively associated
with complications.
Considering generalizability, the characteristics of
the setting have an effect on the direct medical costs of
the patients. Therefore, the characteristics of the hos-
pital should be evaluated. Ampawa Hospital, for
example, has no specialists for treating diabetes and its
complications (such as an ophthalmologist). The dia-
betic drugs used were not advanced, were locally
made, and were available only in a limited number.
The hospital had no special health-care team to care
for diabetic patients neither. This kind of situation
might affect direct medical costs. If the characteristics
of the hospital changed, the direct medical cost would
also change. Bigger hospitals naturally have specialists
of diabetes, more types of drugs (some of which are
brand-name drugs), and a health-care team caring for
diabetic patients. Thus, the average direct medical cost
of caring for patients at tertiary services, e.g., provin-
cial hospitals, was expected to be higher than that of
patients at Ampawa Hospital.
In attempt to extrapolate the country cost based on
this study, the similarity of the proportions of cost
between the study hospital and other same level hos-
pitals was considered. When comparing the propor-
tions of labor (60%), material (29%), and capital
(11%) costs obtained from this study with those from
the study performed at 17 community hospitals [52],
which are of the same hospital level, the proportions of
labor (53%), material (38%), and capital (10%) were
not quite different. In addition, the annual average cost
from the study hospital could also be used to represent
as the cost of all community hospitals in Thailand.
Based on the study estimating diabetic outpatient
charges of one regional hospital (900 beds) and 17
community hospital covering 900,000 outpatient
visits, it was found that charge per visit of the regional
hospital was 3.48 times of those of the community
hospitals (mean = 1180.6 THB and 339 THB at 2002
prices, respectively) [53]. This ratio and the cost of
diabetes resulting from the study hospital can be
applied for estimation of average treatment cost of
diabetes in regional hospitals.
Conclusions
Bigger hospitals naturally have specialists of diabetes,
more types of drugs (some of which are brand-name
drugs), and a health-care team caring for diabetic
patients. In addition, the study demonstrated cost-
effectiveness of prevention/screening of complications.
Nevertheless, there might be limitations on the gener-
alizability of the model because of differences in facil-
ity characteristics resulting in different resource
utilization pattern.
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